Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients
Alexander C. J. van Akkooi(The University of Sydney), Alexander M.M. Eggermont(University Medical Center Utrecht), Wanda Michej(European Organisation for Research and Treatment of Cancer), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Gregor Schäfer-Hesterberg(Humboldt-Universität zu Berlin), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Cornelis Verhoef(Erasmus MC Cancer Institute), Johannes H. W. de Wilt(Radboud University Nijmegen), Christiane Voit(Humboldt-Universität zu Berlin)
Cited by 254
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k